Global Arachnoiditis Treatment Market, By Drug Class (NSAIDs (non-steroidal anti-inflammatory drugs), corticosteroids., anti-spasm drugs., anti-convulsant drugs), Disease Type (Adhesive Arachnoiditis, Arachnoiditis Ossificans, Cerebral Arachnoiditis, Hereditary Arachnoiditis, Neoplastic Arachnoiditis, Optochiasmatic Arachnoiditis), Treatment (Pain Management, Physiotherapy, Psychotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Arachnoiditis Treatment Market Analysis and Size
The global arachnoiditis treatment market is expected to witness significant growth during the forecast period. This condition is quite common in people between 40 and 60 years old. It is a rare condition and the associated risk factors include AIDS, diabetes, alcoholism, chemotherapy, and organ transplantation. The occurrence of arachnoiditis is low; however, around 25,000 cases occur annually in North & South America, Asia, and Europe. A sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of global arachnoiditis treatment market.
Data Bridge Market Research analyses a growth rate in the global arachnoiditis treatment market in the forecast period 2022-2029. The expected CAGR of global arachnoiditis treatment market is tend to be around 3.50% in the mentioned forecast period. The market was valued at USD 2.3 billion in 2021, and it would grow upto USD 3.03 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Arachnoiditis is a type of spinal disorder that is characterized by chronic inflammation of the arachnoid tissue. It can occur due to the arachnoid's bacterial, viral or fungal infections. In this diseased conition, patient generally experience chronic pain in their lower back and legs. Symptoms include burning pain in lower legs, numbness, tingling, and in some people, this condition causes paralysis in the legs. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.
Arachnoiditis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (NSAIDs (non-steroidal anti-inflammatory drugs), corticosteroids., anti-spasm drugs., anti-convulsant drugs),Disease Type (Adhesive Arachnoiditis, Arachnoiditis Ossificans, Cerebral Arachnoiditis, Hereditary Arachnoiditis, Neoplastic Arachnoiditis, Optochiasmatic Arachnoiditis), Treatment (Pain Management, Physiotherapy, Psychotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Mallinckrodt plc (U.K.), Apotex Inc (Canada)
|
|
Market Opportunities
|
|
Global Arachnoiditis Treatment Market Dynamics
Drivers
- Increased Government Initiatives
Governments and numerous organizations take several initiatives to spread awareness about arachnoiditis that are estimated to boost the growth of the global arachnoiditis treatment market. For instance, the State of Michigan declared Arachnoiditis Awareness Month every year, aiming to create utmost awareness about the disease and its associated treatment, thus boosting the market growth.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global polymyalgia rheumatic treatment market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.
Opportunities
- Increased Advanced Diagnostic Technology
Technological advancements and increased awareness about proper diagnosis of the disease are likely to boost the global arachnoiditis treatment market. Adoption of several diagnostic tools such as inflammatory markers and magnetic resonance imaging (MRI) are most likely to create opportunities for the global market. All these factors are also contributing in the growth of the market.
- Increase in Elderly Population
Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global arachnoiditis treatment market over a forecast period.
- Unavailability of Appropriate Treatments
To treat rare conditions, many treatments are not available, especially in the under-developed countries. Severe patients needs to be treated with advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.
This global arachnoiditis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global arachnoiditis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Arachnoiditis Treatment Market
During the pandemic, it has been witnessed that besides the pulmonary, renal, and hematological complications, gastrointestinal, there has been also a record of neurological appearances have also been reported frequently. Weakness, sensory deficit, autonomic dysfunction, sphincter dysfunction and ataxia were the most common neurological signs in the patients. Pathogenetic mechanisms responsible for developing spinal cord demyelinating diseases after SARS-CoV-2 infection may be either mediated by direct neurotropism or by unusual immune-mediated injury. Even though the pandemic is not there much, but the effect of this disease is still there. Thus, COVID-19 left a major impact on global arachnoiditis treatment market.
Global Arachnoiditis Treatment Market Scope
The global arachnoiditis treatment market is segmented on the basis of disease type, treatment, route of administration,end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
(NSAIDs (non-steroidal anti-inflammatory drugs)
- Ibuprofen
- Naproxen
- diclofenac
Corticosteroids
- Aristocort.
- Bubbli-Pred
- Celestone
- Cortone Acetate
Anti-spasm drugs
- Dicycloverine
- Hyoscine
- Atropine
- Propantheline
Anti-convulsant drugs
- Carbamazepine
- Oxcarbazepine
- Lamotrigine
Disease Type
- Adhesive Arachnoiditis
- Arachnoiditis Ossificans
- Cerebral Arachnoiditis
- Hereditary Arachnoiditis
- Neoplastic Arachnoiditis
- Optochiasmatic Arachnoiditis
Treatment
- Pain Management
- Physiotherapy
- Psychotherapy
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Arachnoiditis Treatment Market Regional Analysis/Insights
The global arachnoiditis treatment market is analysed and market size insights and trends are provided by disease type, treatment, route of administration,end-user, distribution channel as referenced above.
The major countries covered in the global arachnoiditis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the high-income of the countries and advanced healthcare facilities.
Asia-Pacific is dominating the market due to the increasing cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Arachnoiditis Treatment Market Share Analysis
The global arachnoiditis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global arachnoiditis treatment market.
Key players operating in the global arachnoiditis treatment market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Mallinckrodt plc (U.K.)
- Apotex Inc (Canada)
SKU-